Company NuGenerex Immuno-Oncology, Inc.

NuGenerex Immuno-Oncology, Inc. is a biotechnology company. The Company is focused on the modulation of the immune system and activation of T cells to treat cancer. It is engaged in developing immunotherapeutic products and vaccines based on its patented platform technology, Ii-Key. The Ii-Key is a peptide derived from the major histocompatibility complex (MHC) Class II associated invariant chain (Ii) that regulates the formation, trafficking, and antigen-presenting functions of MHC class II complexes, essential for the activation of T cells in the immune response. The Company's lead immunotherapy product candidate is AE37, an Ii-Key-HER2 peptide vaccine for breast, prostate, and bladder cancer. AE37, an Ii-Key-HER2 vaccine that contains the HER2/neu antigenic peptide linked to the Ii-Key to enhance immune stimulation against HER2, which is expressed in numerous cancers.

Number of employees: 6